N-benzenesulfonyl-N-phenethyl-glycine | 119811-30-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzenesulfonyl-N-phenethyl-glycine
• 英文别名: N-Benzolsulfonyl-N-β-phenaethyl-glycin；N-Benzolsulfonyl-N-phenaethyl-glycin；N-(2-phenylethyl)-N-(phenylsulfonyl)glycine；2-[benzenesulfonyl(2-phenylethyl)amino]acetic acid
• CAS: 119811-30-2
• 化学式: C₁₆H₁₇NO₄S
• mdl: MFCD01060562
• 分子量: 319.381
• InChiKey: NUIZYVHNJDAMKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-benzenesulfonyl-N-phenethyl-glycine 在 磷酸酐 、 xylene 作用下， 生成 1,2,3,4-tetrahydro-2-(phenylsulfonyl)isoquinoline
  参考文献：
  名称：

  v.Braun; Bayer, Chemische Berichte, 1927, vol. 60, p. 1262

  摘要：

  DOI：
• 作为产物：
  描述：

  2-苯乙胺 在 盐酸 作用下， 生成 N-benzenesulfonyl-N-phenethyl-glycine
  参考文献：
  名称：

  DE423027

  摘要：

  公开号：

文献信息

• Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis
  作者：R. Félix Toledo、J.M. Negro Álvarez、J.C. Miralles López

  DOI：10.1016/s0301-0546(02)79097-6

  日期：2002.1

  The causal role of immunoglobulin E (IgE) in triggering the cascade of biochemical events leading to allergic disease is well established. Treatments that selectively inhibit IgE activity are a logical approach in managing the allergic response. Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the Cε3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, Omalizumab, was assessed in patients with moderate-to-severe allergic asthma and seasonal allergic rhinitis. Intravenous and subcutaneous administration of anti-IgE mAb reduces circulating levels of IgE in atopic patients to low levels commonly seen in non-atopic individuals. Anti-IgE therapy offers protection against allergen-induced bronchoconstriction, reduces the need for short acting inhaled beta 2-agonist and corticosteroids among asthmatic patients and reduces severity of symptoms of allergic rhinitis. Adverse events were infrequent in clinical trials of omalizumab, and not significantly different from placebo. The most frequent drug-related event was mild to moderate urticaria. They do not induce anaphylaxis and the occurrence of antibodies against anti-IgE mAb is sporadic. The results of cited studies suggest that humanized anti-IgE monoclonal antibodies may have important immunotherapeutic benefit for treatment of allergic disorders.
• v. Braun; Blessing; Cahn, Chemische Berichte, 1924, vol. 57, p. 910
  作者：v. Braun、Blessing、Cahn

  DOI：——

  日期：——
• DE423027
  申请人：——

  公开号：——

  公开（公告）日：——
• v.Braun; Bayer, Chemische Berichte, 1927, vol. 60, p. 1262
  作者：v.Braun、Bayer

  DOI：——

  日期：——